Home / Transcripts / IMCD N.V. (IMCD) · April 30, 2026

IMCD N.V. (IMCD) Earnings Call Transcript

April 30, 2026

Euronext Amsterdam NL Industrials Trading Companies and Distributors earnings 50 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone. Thank you for joining IMCD's conference call covering results for the first 3 months of 2026. Your hosts today are Marcus Jordan, our CEO, and Hans Kooijmans, our CFO. During this opening portion, everyone will be in listen-only mode, and a question-and-answer session will follow. Should you want to pose a question, simply press *5 on your telephone keypad. At this point, I'll turn things over to Marcus Jordan. Mr. Jordan, the floor is yours.

Marcus Jordan executive
#2

Thanks a lot, Arjan. Hello everyone, and welcome. I’m Marcus Jordan, and joining me today is our CFO, Hans Kooijmans, to discuss the results for the first 3 months of 2026, which we released in a press release earlier this morning. I’ll keep my opening remarks brief so there’s enough time for Q&A, since our AGM follows right after this meeting, which means we have a hard stop at 10:00. In our first quarter, the first quarter of 2026, we delivered solid results against a strong Q1 2025 comparable, and I’m pleased to report an increase in free cash flow and a robust cash conversion margin. On the previous full-year call, we mentioned positive conversations with our suppliers and customers about the demand outlook and green shoots potentially coming our way. Since that full-year call, a lot has happened: there have been some reversals in tariffs following the court ruling that deemed the tariffs illegal, an introduction of other tariffs, and then the conflict in the Middle East, which has created further uncertainty and quite some changes in the market dynamics. Focusing on the Middle East, since the conflict began, we have seen a significant amount of price increases, which can be broken down into two categories: firstly, the direct impact of fuel increases on transportation costs; and secondly, an increase in the cost of the product itself as the cost of the raw materials and energy costs needed in the manufacturing processes have both risen.

Marcus Jordan executive
#3

Like before, whenever we get increases, we can spot them fast and hand them along. Given how many increases we've got coming in, people often liken things to the post-COVID period, but it's worth pointing out that back then the hikes were mostly a matter of pent-up demand, and that isn't really the situation today. In Q1 we saw no meaningful pre-buying, though there are a few signs of it as we move into Q2. Still, the increase is fairly modest, since we think customers took some lessons from the post-COVID years, when they pre-bought too much inventory at high prices. The big question ahead is how the conflict will affect end-consumer confidence and therefore demand, which in the end is the largest driver of our business. So our outlook is cautious. Turning to the first 3 months of 2026, slide 4 gives you a summary of our financial results. Gross profit came in at €312 million, up 1% on a constant currency basis. EBITA was below last year at €130 million, as our lower cost in the first 3 months of 2026 could not fully offset the decline in reported gross profit.

Marcus Jordan executive
#4

I'm glad to say free cash flow rose to €121 million, which gave us a cash conversion margin of nearly 91%. Turning now to M&A, we closed two acquisitions during the first 3 months of this year. The first was Donyang FT in South Korea, a beauty and personal care business with 14 people and €34 million in revenue. That marks our second beauty and personal care deal in South Korea in a year, and it makes us stronger in one of the biggest and most innovative beauty and personal care markets anywhere in the world. The second was Willow Ingredients in the UK and Ireland, a food and nutrition company with 26 people and €30 million in revenue. That one is exciting because it builds our capabilities in specialised health, sports, and animal nutrition. To wrap up my part of the introduction, in these unpredictable times it's essential that we stay a reliable partner for customers and suppliers alike and that we adapt quickly when market conditions change. We keep our focus on what we can control so we can deliver long-term growth to our partners and stakeholders in the years ahead.

Marcus Jordan executive
#5

At this point, I'd like to pass things over to Hans Kooijmans, our CFO, for an update on the numbers.

Hans Kooijmans executive
#6

Thank you for that introduction, Marcus. Good morning, ladies and gentlemen. I'm glad to provide a brief overview of IMCD's trading update for the first quarter, beginning on page 6 of the analyst call presentation. Marcus has already mentioned the challenging market conditions and last year's comps. As we explained during our 2025 full-year analyst call in February, those challenging conditions overlapped with considerable currency headwinds. This slide shows how the negative translation impact from foreign exchange creates a notable gap between reported and forex-adjusted figures. You may also remember that in the comparison of Q1 this year against Q1 last year, the weakening of the US dollar in particular hurt sales values across several regions. Under these conditions, we are certainly not satisfied with the reported outcome. Still, it represents a solid start to the year. As you can see, forex-adjusted revenue rose 6% and gross profit rose 1% in the first quarter of this year. That gross profit increase combined a 4% organic decline with 5% from the first-time inclusion of companies acquired in 2025 and 2026. The gross margin percentage for the first quarter is 24.6%, and as you can see, that is 1.2% below Q1 last year.

Hans Kooijmans executive
#7

Roughly half of that percentage decline comes from companies we recently acquired, which carry lower gross profit margins on average. The gross margin percentage for this first quarter — 24.6% — is a bit above the 24.2% we reported in the second half of last year. That percentage gain versus the second half of last year came from a mix of product mix shifts, local market conditions, and internal initiatives to improve gross margin that helped push the margin percentage higher. Then forex-adjusted operating EBITA fell 2% to €130 million, while the operating EBITA margin declined to 10.2% and the conversion margin dropped to 41.6%. Lower organic own cost during the first 3 months of 2026 was not enough to fully offset the drop in reported gross profit. Speaking of own cost reduction, at the bottom of this slide you can see that our headcount rose by 112 employees, up 2%, and that increase stems from acquisitions. As Marcus and I anticipated on earlier calls, on a like-for-like basis we trimmed employee numbers slightly versus last year. Forex-adjusted net result was down 3% to €63 million. Later I'll return to free cash flow, which is genuinely healthy for a first quarter.

Hans Kooijmans executive
#8

Cash earnings per share for Q1 came in at €1.46, which is a reported drop of 6% versus last year. If you normalize for the forex impact, cash earnings per share would have come in around the same level as last year. On the next slide, slide 7, you'll see several key figures from the P&Ls by operating segment, and, as always, with attention on gross margin and EBITA development. I've already touched on the currency headwind. As this slide shows, the negative translation impact is largest in the Americas and APAC. EMEA is the sole operating segment posting modest growth in gross profit and EBITA. Gross margin in EMEA fell by 0.9% to 26.6%. If I were to normalize for the effect of the recent acquisitions in EMEA, the gross margin percentage would have come in a bit above the first 3 months of 2025. Organic own cost in EMEA was somewhat below last year's level in Q1, and the slight organic decline in EBITA in EMEA was therefore driven by differences on other P&L lines, such as doubtful debt provisions, other operating income, and somewhat higher third-party costs. As a result, all EBITA-related ratios declined slightly relative to the same period a year earlier.

Hans Kooijmans executive
#9

Over in the Americas, we're reporting a significant negative organic growth in both gross profit and EBITA. That comes from a mix of factors, including the more industrial and volatile business mix as well as a very strong Q1 in 2025. You may recall that last year Marcus and I had to explain how we managed to grow EBITA in the Americas by more than 20% organically. I'm somewhat worried you'll now ask us during the Q&A to explain the decrease of 20%-plus. You can imagine I'd rather be explaining double-digit growth here, but unfortunately that hasn't been the case so far. Then Asia-Pacific in the third column, where you can see that the positive effect of acquisitions is more than offset by negative currency impact. Organic EBITA and gross profit were roughly flat versus last year. Then in the final column, under Holding companies, you'll find all non-operating companies, including the head office in Rotterdam. In Q1, holding costs came to 0.6% of revenue, compared with 0.8% last year. On page 8, there's a summary of IMCD's free cash flow. As mentioned earlier, free cash flow in Q1 was €19 million better than last year. Taking into account the typical working capital cycle through the year, a Q1 cash conversion ratio above 90% could be regarded as very healthy.

Hans Kooijmans executive
#10

The drop in adjusted operating EBITA of €11 million was more than offset by reduced investment in working capital. Capital expenditure came in at €1 million, a bit below the prior year. On page 9, a brief update on net debt and leverage: reported leverage ratios, along with the leverage ratios calculated under the loan documentation definitions, were close to the 2025 year-end figures, at 2.8 and 2.7 times LTM EBITDA. Then, last but not least, page 11 contains our outlook. I imagine you have already gone through it yourselves while reading our press release. To sum up, as Marcus also said, we are positive yet cautious. That is the brief summary of our financials. Marcus and I are glad to take your questions. Over to Arjan.

Operator operator
#11

Ladies and gentlemen, we're ready now to take your questions. Should you want to ask something, just press *5 on your phone's keypad. Our first question is from Anil Shenoy at Barclays. Anil, please go ahead.

Anil Shenoy analyst
#12

Hello, and good morning, Marcus. Good morning, Hans. I appreciate your taking my questions. I have just 2, please. First, could you provide some detail regarding what we should expect in Q2? My reason for asking is that a competitor of yours said last week they had begun to observe supply chain disruptions within the system, and they anticipate this will help their financials in Q2, while it provided no benefit in Q1. They further noted that they have not yet realized any benefit, but they expect it to arrive at some point later in Q2, and that the full impact will likely become visible in Q3. Do you broadly agree with that view, or are you observing anything comparable? If you could offer a comment on that, please. That is my first question. My second question, on a related matter, is that even absent supply chain disruptions, a number of European producers have raised prices for their chemicals, with BASF the most recent, and they said on the call roughly an hour ago that they have increased prices and they expect this, again, to affect their financials in Q2. Even without the disruptions, and with only these price increases, I would anticipate that IMCD and Azelis would benefit, given the opacity in the pricing model.

Anil Shenoy analyst
#13

Is that correct? If it isn’t, perhaps you could add some detail around it. Thank you.

Marcus Jordan executive
#14

Morning, Anil, and many thanks for those questions. Naturally, we won't be sharing a great deal of detail regarding, say, how Q2 looks overall, but I can tell you that the quarter has begun solidly. When it comes to supply chain disruptions — whether at IMCD or at one of our competitors — handling them is genuinely among the capabilities we bring. Being a distribution company, we're nimble and quick to act, we obviously hold inventory locally, and as you know we're now well accustomed to just-in-time delivery and to serving as the partner of choice for both the customer and the supplier. The Middle East crisis is, of course, terrible, yet the market disruption, I'd argue, is if anything something that suits the business's wheelhouse. So then, as I mentioned earlier, we really concentrate on what we're able to control. The teams, I'd say, are extremely busy. That leads into my second point: we can definitely confirm the very high number, and in certain instances the absolute amount, of the price increases we've received.

Marcus Jordan executive
#15

Honestly, this got off to a fairly slow start, because the European manufacturers in particular had put a lot of time and effort into either holding onto or expanding their market share across the past 1 to 2 years. Once the Middle East crisis began and people assumed it would be short-term, a fair number of suppliers were delaying their increases, even if they themselves were possibly bearing extra cost. As the crisis has dragged on, the count and size of those increases have risen quite substantially. I think you could fairly say that not getting a price increase has become, I'd argue, the exception rather than the rule. Breaking it down by region, I'd say the level is lower in North America than in the other two regions.

Anil Shenoy analyst
#16

Yes, thanks for that. Just one quick follow-up question. Could you confirm that IMCD actually benefits from these price increases?

Marcus Jordan executive
#17

I believe you've observed historically that during periods of pricing volatility, we as a distributor tend to do well for a range of reasons. Naturally, there's always a trade-off involved in ensuring we remain — as I mentioned — that long-term partner to both customers and suppliers. Each situation really gets evaluated individually, but yes, whenever we can, we aim to capitalize on it.

Anil Shenoy analyst
#18

Thanks a lot, Marcus. That's really helpful.

Marcus Jordan executive
#19

Thanks.

Operator operator
#20

Annelies Vermeulen with Morgan Stanley has the next question. Annelies, the floor is yours.

Annelies Vermeulen analyst
#21

Hi, good morning, Marcus. Morning, Hans. Two questions, please. First, a quick follow-up on those price increases. Can you quantify how substantial they are? Are we talking 5%, 10%, 15%, or is this 30%, 40%, 50%? I appreciate it will vary enormously by product type and probably end market, but any kind of range would be useful. Then secondly, also on the supply chains, are you seeing any supply issues or shortages as yet, any products that you're already seeing some pressure? Is it fair to say that you'll expect to see more shortages through Q2? Thank you.

Marcus Jordan executive
#22

Annelies, that initial question is quite hard to respond to, since as you noted, it really depends heavily on the specific product. I believe you're able to see in the press, from a lot of our suppliers, what levels of increases are taking place, and that range is extremely wide, covering pretty much every figure you just mentioned. Regarding supply chain matters and shortages, we have not yet seen shortages, but it's reasonable to say that the amount of discussion surrounding possible shortages is starting to grow. I think it's worth repeating that even certain very basic chemicals — and we all hear methanol cited as an example, a pure commodity that of course we're not involved with — but methanol as a solvent is very tight, especially in the Asia-Pacific region. A basic solvent like that feeds into the production of many specialty products. While we were at in-cosmetics the week before last, some of our Asia-Pacific suppliers started to mention methanol shortages and perhaps a future effect on their capacity to make the specialties. I think right now, it's a situation where we don't see it, but concern is growing among people as the conflict goes on.

Annelies Vermeulen analyst
#23

I appreciate that.

Operator operator
#24

Suhasini Varanasi from Goldman Sachs has the next question. Suhasini, please proceed.

Suhasini Varanasi analyst
#25

Good morning, and thanks for taking my questions. First, regarding the organic GP declines of minus 4% that you reported for the quarter: could you help us understand how those declines developed as the quarter went on? Was March perhaps stronger than January and February? And if so, in which geographies or verticals did you observe the most material change? I understand you don't provide any guidance on 2Q as such, but can you offer any colour on whether organic GP has turned positive yet in 2Q? My final question concerns working capital investments. With all the concerns about product shortages, do you expect greater requirements for working capital — inventory, perhaps — simply to ensure you can navigate the coming few quarters effectively? Thank you.

Marcus Jordan executive
#26

Thanks for the questions. On the split across the first quarter — we don't provide much of a month-by-month breakdown — but I think it's reasonable to say the year began more softly than we'd anticipated, especially given that 2025 ended on a fairly soft note, and then we saw a nice pickup as the quarter progressed. As for the Q2 outlook, I think I've already said as much as I really want to say on that. Regarding working capital levels, it's really about ensuring we have the right inventory on hand so we can meet customers' demands. As you can imagine, customer forecasts are very short-term, or in some cases not visible at all, but we're working very closely with those customers to try and ensure the right inventory is in place, while also working with suppliers to make sure we don't over-order product from them, which would then create a shortage down the road. It's very much about communication and, again, being agile and fast-acting in everything we do from a supply chain perspective. I think, Hans, we're pretty comfortable with the working capital.

Hans Kooijmans executive
#27

Suhasini, I genuinely hope that by the close of Q2 we'll be able to report working capital that's significantly higher, and the driver of that would be considerably larger debtor positions resulting from stronger sales. That's the ideal outcome, naturally, and in that case I'd be glad to report a bigger working capital position. Looking at where we stood at the end of Q1, we've never given out specific figures regarding working capital positions, but I think it's reasonable to say our stock days looked much like what we disclosed at year-end. The modest uptick we observed stemmed from larger debtor positions, which came about thanks to stronger sales in March. My hope is that this trend carries on going forward. If so, I'll be pleased to report somewhat more working capital attributable to more debtors — not on account of higher debtor days, but on account of greater sales.

Suhasini Varanasi analyst
#28

Got it. Thanks.

Operator operator
#29

Matthew Yates of Bank of America is up next with a question. Matthew, the floor is yours.

Matthew Yates analyst
#30

Hey, good morning, everyone. Hans, I actually wanted to follow up on that working capital comment, since we don't have the balance sheet, and I was going to ask you about the breakdown. First, it's a little bit counter-intuitive that your free cash flow is very good despite working capital days being up by 3 year-on-year. Are there any other moving parts that would explain that? Second, in terms of that working capital, if you've seen better momentum through the quarter and order intake as you suggested on the receivables, why has that not come through in the inventory position yet? Were you, I don't know, trying to clean up older stock, and that's maybe offset some of the extra buffer that you may have been securing supply or to fill orders? Thank you.

Hans Kooijmans executive
#31

Matthew, we usually give a complete balance sheet two times each year, and Q1 and Q3 really function for us as a trading update so you get a sense of where things stand. Looking at working capital days, as I mentioned earlier, stock days are more or less flat. We handle our inventory with a lot of caution, as Marcus said before. Right now we're seeing supply chain problems, which also means we can turn stocks faster and move them out of the warehouses again more quickly. As for the days we've reported and will report based on our half-year figures, I don't anticipate material changes there. So that brings me back to the point I raised earlier. I expect to report a higher debtor position, since sales are higher with debtor days staying similar. We aren't seeing collection problems or anything of that kind. This is simply ordinary business. Another thing to keep in mind is that a working capital position at a month-end or quarter-end is only a snapshot of one particular moment. Paying a creditor right before or right after a quarter-end could affect those kinds of days.

Matthew Yates analyst
#32

Alright, let me ask a follow-up there, Hans. When we look back at that earlier supply chain cycle that came after COVID, when there was a lot of price inflation across the industry, how much can something like inventory revaluation actually move the numbers in the very short term?

Hans Kooijmans executive
#33

No. Taking speculative equity positions—betting that prices will rise later—isn’t what our business is about. Our ordering patterns rest on demand that our customers have usually confirmed. So when we set prices with customers at a given moment, we also attempt to set them with suppliers at that same time. One place where we might gain a little is old stock sitting in the warehouse that we can clear out—inventory purchased at a lower price and then sold at a somewhat higher one—yet in most cases that is immaterial relative to the overall margin we produce. I think you’d observe this more in the more commodity-type businesses, where people genuinely take a position and begin betting on shortages in methanol, as an example, take a position, and then hope to sell at a higher price. That is not the business we are in.

Matthew Yates analyst
#34

Thanks to you both.

Operator operator
#35

Our next question is from David Kerstens at Jefferies. David, please go ahead.

David Kerstens analyst
#36

Yes, good morning, gentlemen. Thank you for taking my questions. I'd like to concentrate on the return to growth in the Asia-Pacific region, which showed 3.5% organic revenue growth. First, are you already seeing any relief as competition fades from Chinese suppliers in semi-specialties in Southeast Asia and perhaps in Brazil as well? Second, I believe you mentioned the reversal of some of the tariffs. Have you already seen any indications of improving performance in India? I recall that Signet was hit quite hard by tariffs in the third quarter of last year, which also affected gross margins. Are you seeing any improvement in that situation already? Thank you very much.

Marcus Jordan executive
#37

Good morning, David. First, on India and the Signet business — yeah, as we said on the full-year call, we expected a more normal ordering pattern to come back in the first quarter, and I can confirm that's what happened. On tariffs generally, I think it's become a bit of a muted point because of the Middle East conflict, but of course that's still, I'd say, to some extent a worry in the background, because there's uncertainty not only around the original tariffs that were imposed and the rebates now being given, but also the new tariffs that were then layered on top and when those come to an end. I think on those tariff discussions, we shouldn't underestimate that there's still some impact there. On the APAC question and potentially — I think your wording was failing China — it's fair to say we've seen restrictions, and we're hearing about more restrictions, on exports out of China for particular product groups. In countries like Brazil and Southeast Asia, we've certainly seen more requests coming through at the start of the second quarter — more requests from customers for, let's say, more local-to-local supply.

Marcus Jordan executive
#38

I wouldn't claim the first quarter took a hit, but once again, talk is starting to grow around supply constraints coming from China, and that might end up working in our favor too.

David Kerstens analyst
#39

Perfect, that works well. Thanks so much.

Operator operator
#40

David Symonds of BNP Paribas is up next with a question. David, the floor is yours.

David Symonds analyst
#41

Thanks. We appreciate your remarks about April and what can be said on that front, along with the comparison to the period after COVID. I suppose that post-COVID stretch divided into 2021, when demand was very strong, and 2022, when we had Russia-Ukraine, a shock to energy prices, and demand that declined gradually over the course of the year. I'm just trying to get a sense of the scale of benefit you might see from the disruption we're witnessing — how comparable is that to 2022, which I guess is somewhat more similar from a macro standpoint? Then on the opex side, how are you progressing with the organic headcount reduction you provisioned in Q4? Have those provisions been worked through yet, or is there more still to come over the remainder of the year? Thanks.

Marcus Jordan executive
#42

Okay. When you examine the parallels and differences around COVID, one thing that stood out was a very strong resemblance on the supply chain side — the disruption itself and how much prices rose, in both the count and the magnitude of those increases. As I said earlier, I believe that plays right into the capabilities our organisation has, and it's extremely important that we move nearer to the customers. There are also opportunities that emerge from this when we demonstrate what we're able to deliver, including from the angle of expanding our supplier base. I'd say there are plenty of positives in that. Beneath all of that, I think there's an open question about consumer demand down the road, and none of us truly has the answer to it, I believe. Two weeks ago I attended in-cosmetics, and there was still a great deal of positivity at that event. Broadly speaking, the conversations remain positive, but the longer this conflict lasts, the more market dynamics are able to shift. Overall, David, once again, we concentrate on what's within our control. The teams, I'd say, are reasonably upbeat right now. And on the organic headcount reduction, Hans touched on that somewhat during the full-year call, where some impact was still carrying over into this year.

Marcus Jordan executive
#43

Overall, I'd say we're quite pleased that the right people are sitting in the right roles. As I noted on the last call as well, we've put additional investment into the commercial team we already have, looking at it both from an internal and an external angle. The organisation we've got in place makes us happy.

David Symonds analyst
#44

Actually, if I could squeeze in one quick follow-up that just came to mind. That digital sales tool you've been rolling out over the course of 2025 — how has uptake looked in the early stretch of 2026? Given the disruption caused by the Iran war, are you seeing more people gravitate toward that tool, or do they tend to reach for the phones first?

Marcus Jordan executive
#45

The sales assistant tool, which we initially deployed across the whole company internally over the course of last year. We're quite pleased with the adoption, I'd say, from an internal standpoint—from the commercial teams exploring how we lift the cross-sell rate and manage to present the right product on the first attempt. Only fairly recently, toward the end of last year, and finishing up at the close of Q1, did we launch this tool externally. We're very happy with, I would say, the customer uptake on the MyIMCD platform, though at the end of the day, we still want to be talking with the customer. It remains very much a blend, but we're pleased with how the tool has been taken up and with the capability to, I think, definitely present a broader selection of products first time around.

David Symonds analyst
#46

That's great. Thank you.

Operator operator
#47

Tristan Lamotte of Deutsche Bank has our next question. Tristan, the floor is yours.

Tristan Lamotte analyst
#48

Hello, and thank you for taking my questions. First, I'd like to hear your perspective on overall demand. You mentioned that Q2 got off to a fairly good start. Do you believe any pre-buying has occurred? One chemical producer suggested that March was quite strong but that April turned much weaker. Have you observed that same sort of pattern, or do you think the trend looks somewhat different from a distributor's standpoint?

Marcus Jordan executive
#49

Like I said earlier, we really didn't observe pre-buying in the first quarter, and I mentioned that we'd gotten off to a solid start in the second quarter, so. I do believe there's a bit of pre-buying happening as the second quarter gets going, but as I also said earlier, I think it's quite muted compared with what we might have anticipated based on the past, because I think customers truly took the lesson to heart as they came out of COVID about pulling in excessive inventory at an elevated price. When we talk with the customers, I think that if the Middle East — when the Middle East crisis comes to an end — you could then see some material price decreases. Again, the longer that the conflict continues, I think the longer those longer-term supply chain disruptions will persist even after the conflict ends. Even if the conflict were to end at the close of this week, I think it would still take quite some months to then recover.

Tristan Lamotte analyst
#50

Thanks. For the second question, I was hoping you might say a little about how things went in the Americas — that region looks fairly soft compared with the others, and softer than your peers. Could you perhaps break out how some of the sub-businesses performed there?

Marcus Jordan executive
#51

Okay. In LatAm, the first quarter was broadly a tough market. On prior calls I’ve noted that Brazil specifically runs above the group average on the semi-specialty side, and it’s fair to say that especially early in the quarter, we saw considerable pricing pressure coming from China, for instance. As I said earlier on this call, that’s a country where we’ve observed a bit of a shift emerging at the start of Q2. There’s also some currency headwind — on the translational side, but still some operational currency headwinds as well. Then looking at North America, you know we’re somewhat more industrially focused there, and demand remains softer in coatings and the construction housing market, for example. There are also some moving parts from a supplier standpoint. Within the US, we’re fairly unique in that we really try to work with suppliers on a coast-to-coast basis. Sometimes we need to make supplier changes where certain suppliers only want to work with us in maybe one or two of the regions within the US, and sometimes we make some difficult decisions there to then work with new partners coast-to-coast, and there’s a bit of a timing impact.

Marcus Jordan executive
#52

That played some part in the Q1 figures. And then, naturally, the largest effect came from what Hans described — the really tough comparison for Q1 of last year.

Hans Kooijmans executive
#53

Tristan, you may have noticed as well that when you put us side by side with a competitor—we won’t say which one, though everyone knows who we mean—we posted organic growth in the Americas of over 20% last year, and this year it was over 20% lower. That competitor did better this year, though also down, but last year they likewise showed a decline in organic growth, and their comparables differ somewhat from ours. Still, what we reported isn’t good, and we’ll work hard to bring it back to something more normal. Right now that region is a bit more volatile for us than the group’s other parts. Sometimes that works in your favor and sometimes it doesn’t, and unfortunately at present we’re on the unfavorable side.

Tristan Lamotte analyst
#54

Understood. Thanks.

Operator operator
#55

Chetan Udeshi from JPMorgan has our next question. Chetan, the floor is yours.

Chetan Udeshi analyst
#56

Hello there, and thanks. Good morning, everyone. I was hoping you could share some detail on the end markets. I recall that a year ago, you were experiencing a tougher situation in beauty and personal care. Given all the volatility today, have any meaningful shifts appeared in any of your major end markets? Broadly, I find it quite interesting lately: when I talk with Marcus and you folks, or with certain other distributors, they tell me, fine, no supply shortages have shown up. Yet at the same moment, we observe enormous price hikes occurring across the industry. Something clearly doesn't add up. Either shortages exist that perhaps you aren't seeing and some rivals aren't seeing, but someone else is, or people are simply expecting those shortages and are trying, or willing, to pay more, which might then create a risk that if supply truly isn't short, matters could unwind very quickly. How do you reconcile that from where you sit? Thank you.

Marcus Jordan executive
#57

Morning, Chetan. Let's take your second question first, on the price increase side. Raw material cost pricing is really what's driving this. Energy costs tied to manufacturing have, of course, risen sharply. You're also seeing the cost of certain base hydrocarbons, and that's essentially driven by crude. I don't think it's driven — certainly it isn't driven, in my view — by opportunistic price increases right now. Raw material costs are very much the driver. On end markets, as we said earlier, if you start with life science, pharma is pretty much normal and resilient. The Indian Signet business, which we already discussed, is getting back to a normal kind of ordering pattern in the first quarter. Food and nutrition had a very strong year last year, so it's a bit of a difficult comp, but we're pleased with how food performed. Beauty has generally been a somewhat softer demand market, though the commentary on beauty at the in-cosmetics show was pretty positive — let's wait and see there. I wouldn't say anything material has changed versus what we discussed on the full-year call regarding the industrial side, which is generally a bit softer, especially in coatings and construction.

Chetan Udeshi analyst
#58

Understood. Thank you.

Operator operator
#59

Nicole Manion from UBS is up next with a question. Nicole, please go ahead.

Nicole Manion analyst
#60

Good morning, and thanks — just a single follow-up, if I may, building on the earlier questions about volumes. Since you observed only limited pre-buying, it appears some underlying volume improvement came through in Q1, yet in the Q2 outlook you may be seeing somewhat more risk to underlying demand, which is understandable given the geopolitical situation. I wonder whether you could help us unpack that demand weakness a little, because it seems stock levels at customers are quite low, if anything, and in fact have been for some time. Perhaps we're about to see some shortages on top of that. How should we think about that volume softness? Is it literally just less product going out of the door? Is there somewhat less innovation going on? Any extra detail there would be great to hear. Thanks.

Marcus Jordan executive
#61

I guess if you think about demand rather than volume, we talked earlier in the year about possible green shoots and more of a narrative building around that. As we moved through the first quarter, before the Middle East conflict, that message was really gaining traction, I'd say. Consumer confidence and demand were broadly expected to keep rising steadily as the year went on. Right now, because of the Middle East conflict, it's really hard to say exactly where we stand on that consumer demand and confidence. Unfortunately, we're somewhat in a wait-and-see position. As I mentioned, it's a bit clouded by what I believe is some pre-buying early in this quarter that we've observed, though again, nothing like what we saw previously. I'd also agree with you that customer stock levels downstream are light and lean, and that's precisely where I think we, as a distributor, play a really key role, since we're viewed as that dependable partner who can deliver just in time. This inventory management, which we've discussed a few times, matters enormously.

Nicole Manion analyst
#62

Thanks.

Operator operator
#63

Quirijn Mulder from ING has our next question. Quirijn, the floor is yours.

Quirijn Mulder analyst
#64

Good morning, everyone. I have two questions. The first one concerns M&A in EMEA. As we understand it, that had a negative effect on your gross profit margin. You said that excluding these acquisitions, gross profit margin development was positive. Looking at these numbers, it seems Thielmann's in Italy is the deciding factor here, with gross profit margins below, I would say, 18%. Is there any explanation for those low gross margins? Is that normal for this company? Will you recover that in the coming period? My second question is about the US as well. What is the reason, then, that your gross profit margin is under so much pressure compared to revenues? Because there's a serious difference here. What we see is a 200 basis points loss in your gross profit margin. If you could explain that a little bit.

Hans Kooijmans executive
#65

Quirijn, I think I should definitely handle the first question. When you look at the acquisitions we made in EMEA, there was Thielmann, there was Ferraris, there was Tecom, and food businesses in Spain. Whenever we announce acquisitions, we usually give some indication of revenue and headcount purchased, and there's sort of a standard practice whereby if the EBITDA margin differs substantially from our typical average, we say something about that as well. No EBIT margin information was provided, but what you're seeing in the numbers now is that these three acquisitions combined had a decent EBIT margin, yet a considerably lower gross margin percentage. That's partly related to the product mix they sell into the market and the kinds of products they make, and it also gives us an opportunity: if we execute well, we ought to be able to raise gross margin percentages in parts of their portfolio where that's feasible under current market conditions, where we could enhance the margin percentage. That's also why I noted in the introduction that we have internal projects aimed at improving margin percentages too.

Hans Kooijmans executive
#66

You may have noticed that our gross margin percentage for Q1 of this year already sits a bit above where it was during the second half of last year. From our standpoint, when you purchase something carrying a lower gross margin — partly tied to product, hard to shift — but wherever change is possible, we make it, and that's visible in the results. Regarding the decline in gross margin percentage across the Americas, turning to Marcus, shall I?

Marcus Jordan executive
#67

Yeah.

Hans Kooijmans executive
#68

The key factor, I'd say, is that a few shifts in the product mix affected the overall margin percentage — what Marcus mentioned, a supplier change, setup, and a timing difference all played some part. Another significant point is how we have to handle currency volatility in that region, which had a negative effect. Quite a few moving pieces are influencing the margin we earn there.

Marcus Jordan executive
#69

Gross margin percentage is obviously a useful indicator, but as I’ve said previously, what we really emphasize and reward internally is the absolute gross margin dollar amount. The rationale there is also to ensure that, as a company, we don’t overlook incremental new wins. You can imagine that when we try to motivate our sales team to go out and bring in new business, fairly often that new business may begin at a lower gross margin percentage than the average for the group. A decline in gross margin percentage does not automatically signal weak business performance, and it matters that we keep that in mind. I think, to restate Hans’s broader point, we are working very hard on enhancing how the Americas performs as a region. More to come.

Quirijn Mulder analyst
#70

Thanks. For that area, your conversion margin has also dropped under 40% at this point, and I can imagine that's a bit concerning.

Hans Kooijmans executive
#71

There's definitely space to do better, Quirijn. Yeah, that's somewhat troubling, though it also leaves room to improve.

Quirijn Mulder analyst
#72

Thanks.

Operator operator
#73

Thanks. So with that, I'll hand things back over to Mr. Jordan now for any closing remarks he'd like to make.

Marcus Jordan executive
#74

Hans and I want to say a big thank you to everyone for being on this morning's call and for your questions, and we hope you all have a very good day. Thank you, everyone.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete IMCD N.V. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to IMCD N.V. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.